Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control (SOTA-CKD3)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03242252 |
|
Recruitment Status :
Completed
First Posted : August 8, 2017
Results First Posted : June 25, 2021
Last Update Posted : June 25, 2021
|
Sponsor:
Lexicon Pharmaceuticals
Collaborator:
Sanofi
Information provided by (Responsible Party):
Lexicon Pharmaceuticals
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
Primary Objective:
To demonstrate the superiority of Sotagliflozin 200 milligrams (mg) and Sotagliflozin 400 mg versus placebo on HbA1c reduction at 26 Weeks in participants with Type 2 diabetes who have inadequate glycemic control and moderate renal impairment.
Secondary Objectives:
- To assess the effects of Sotagliflozin 200 mg and 400 mg versus placebo with respect to additional measures of glycemic control, blood pressure, and body weight.
- To evaluate the safety of Sotagliflozin 200 mg and 400 mg versus placebo.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Type 2 Diabetes Mellitus Chronic Kidney Disease Stage 3 | Drug: Placebo Drug: Sotagliflozin | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 787 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Mellitus and Moderate Renal Impairment Who Have Inadequate Glycemic Control |
| Actual Study Start Date : | August 16, 2017 |
| Actual Primary Completion Date : | March 25, 2019 |
| Actual Study Completion Date : | October 25, 2019 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Type 2 diabetes
| Arm | Intervention/treatment |
|---|---|
|
Placebo Comparator: Placebo
Following a 2-week run-in period, participants received two placebo tablets (identical to sotagliflozin 200 mg in appearance), orally once daily, before the first meal of the day for up to 54 weeks.
|
Drug: Placebo
Placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily. Route of administration: Oral |
|
Experimental: Sotagliflozin 200 mg
Following a 2-week run-in period, participants received two tablets, 1 sotagliflozin 200 mg tablet and 1 placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily, before the first meal of the day for up to 58 weeks.
|
Drug: Placebo
Placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily. Route of administration: Oral Drug: Sotagliflozin Sotagliflozin 200 mg, tablet, orally once daily. Route of administration: Oral Other Name: SAR439954 |
|
Experimental: Sotagliflozin 400 mg
Following a 2-week run-in period, participants received sotagliflozin 400 mg, administered as two 200 mg sotagliflozin tablets, orally once daily, before the first meal of the day for up to 60 weeks.
|
Drug: Sotagliflozin
Sotagliflozin 200 mg, tablet, orally once daily. Route of administration: Oral Other Name: SAR439954 |
Primary Outcome Measures :
- Change From Baseline in HbA1c at Week 26 [ Time Frame: Baseline to Week 26 ]An Analysis of covariance (ANCOVA) model was used for analysis.
Secondary Outcome Measures :
- Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 [ Time Frame: Baseline to Week 26 ]An ANCOVA model was used for analysis.
- Change From Baseline in SBP for Participants With Baseline SBP ≥130 mmHg at Week 12 [ Time Frame: Baseline to Week 12 ]An ANCOVA model was used for analysis.
- Change From Baseline in SBP at Week 12 for All Participants [ Time Frame: Baseline to Week 12 ]An ANCOVA model was used for analysis.
- Change From Baseline in Body Weight at Week 26 [ Time Frame: Baseline to Week 26 ]An ANCOVA model was used for analysis.
- Percentage Change From Baseline in the Urine Albumin: Creatinine Ratio (UACR) at Week 26 in Participants With Baseline UACR >30 Milligrams Per Gram (mg/g) [ Time Frame: Baseline to Week 26 ]An ANCOVA model was used for analysis. No Measure of Dispersion was pre-specified to be calculated.
- Percentage of Participants With HbA1c <6.5% at Week 26 [ Time Frame: Week 26 ]
- Percentage of Participants With HbA1c <7.0% at Week 26 [ Time Frame: Week 26 ]
- Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) [ Time Frame: Up to 60 weeks ]
Other Outcome Measures:
- Percentage of Participants With Hypoglycemic Events [ Time Frame: Up to 60 weeks ]Percentage of participants with hypoglycemic events are reported for the following 3 categories: Any hypoglycemia (as reported in the Electronic Case Report Form); Documented symptomatic hypoglycemia [typical symptoms of hypoglycemia (increased sweating, nervousness, asthenia/weakness, tremor, dizziness, increased appetite, palpitations, headache, sleep disorder, confusion, seizures, unconsciousness, and/or coma) and plasma glucose ≤ 70 mg/dL (3.9 mmol/L)]; Severe [an event requiring assistance of another person to actively administer carbohydrate, glucagon, intravenous glucose or other resuscitative actions] or documented symptomatic hypoglycemia [typical symptoms of hypoglycemia and plasma glucose ≤ 70 mg/dL].
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion criteria :
- Participants with Type 2 Diabetes (drug-naïve or on antidiabetic therapy) and documented moderate renal insufficiency defined by an estimated glomerular filtration rate (eGFR) (based on the 4 variable Modification of Diet in Renal Disease (MDRD) equation) of ≥30 and <60 milliliter per minute (mL/min)/1.73 meter square (m^2) (chronic kidney disease [CKD] 3A, 3B).
- Participants has given written informed consent to participate in the study in accordance with local regulations.
Exclusion criteria:
- Hemoglobin A1c (HbA1c) of <7.0% or >11.0%.
- Type 1 diabetes.
- Women of childbearing potential (WOCBP) not willing to use highly effective method(s) of birth control during the study treatment period and the follow-up period, or who are unwilling or unable to be tested for pregnancy during the study.
- Treatment with a sodium-glucose cotransporter type 2 (SGLT2) inhibitor (Canagliflozin, Dapagliflozin, Empagliflozin) during the last 12 months.
- Uncontrolled high blood pressure.
- Participants with severe anemia, severe cardiovascular (including congestive heart failure New York Heart Association IV), respiratory, hepatic, neurological, psychiatric, or active malignant tumor or other major systemic disease or patients with short life expectancy that, according to the Investigator, will preclude their safe participation in this study, or will make implementation of the protocol or interpretation of the study results difficult.
- Lower extremity complications (such as skin ulcers, infection, osteomyelitis and gangrene) identified during the Screening period, and still requiring treatment at Randomization.
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03242252
Locations
Show 170 study locations
Sponsors and Collaborators
Lexicon Pharmaceuticals
Sanofi
Investigators
| Study Director: | Suman Wason, MD | Lexicon Pharmaceuticals, Inc. |
Study Documents (Full-Text)
Documents provided by Lexicon Pharmaceuticals:
Documents provided by Lexicon Pharmaceuticals:
Study Protocol [PDF] December 22, 2017
Statistical Analysis Plan [PDF] November 27, 2019
| Responsible Party: | Lexicon Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT03242252 |
| Other Study ID Numbers: |
EFC14837 2016-004889-26 U1111-1187-8662 ( Other Identifier: UTN ) |
| First Posted: | August 8, 2017 Key Record Dates |
| Results First Posted: | June 25, 2021 |
| Last Update Posted: | June 25, 2021 |
| Last Verified: | May 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Kidney Diseases Renal Insufficiency, Chronic Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
Urologic Diseases Renal Insufficiency (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol Sodium-Glucose Transporter 2 Inhibitors Molecular Mechanisms of Pharmacological Action Hypoglycemic Agents Physiological Effects of Drugs |